# Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

> **NCT04982068** · PHASE1 · UNKNOWN · sponsor: **Shanghai Zerun Biotechnology Co.,Ltd** · enrollment: 72 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** 202-CoV low adjuvant dose
- **BIOLOGICAL:** 202-CoV low antigen dose
- **BIOLOGICAL:** 202-CoV standard dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04982068
- **Lead sponsor:** Shanghai Zerun Biotechnology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-12
- **Primary completion:** 2021-10-31
- **Final completion:** 2023-06
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2023-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982068, "Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04982068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*